ArticleNature communications2016
Treatment of ongoing autoimmune encephalomyelitis with activated B-cell progenitors maturing into regulatory B cells.
Article in Nature communications, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 36 citations in OpenAlex.
- Selective decreases in regulatory B-cell (Breg) subsets in active uveitis: IL-10+CD19+CD24hiCD38hiBregs in patients and B10 Bregs in mice.International immunology · 2026Article
- Use of regulatory cells for achieving functional tolerance of pig heart xenotransplants in humans: a literature review.Frontiers in immunology · 2025Review
- Human regulatory memory B cells defined by expression of TIM-1 and TIGIT are dysfunctional in multiple sclerosis.Frontiers in immunology · 2024Article
- PD-L1 is required for estrogen-induced protection against severe EAE in IL-10 deficient miceMetabolic brain disease · 2023Article
- When the allergy alarm bells toll: The role of Toll-like receptors in allergic diseases and treatment.Frontiers in molecular biosciences · 2023Review
- Aglycosylated extracellular loop of inwardly rectifying potassium channel 4.1 (KCNJ10) provides a target for autoimmune neuroinflammation.Brain communications · 2023Article
- Activated B cells suppress T-cell function through metabolic competition.Journal for immunotherapy of cancer · 2022Article
- Balance between immunoregulatory B cells and plasma cells drives pancreatic tumor immunity.Cell reports. Medicine · 2022Article
- CpG-Activated Regulatory B-Cell Progenitors Alleviate Murine Graft-Versus-Host-Disease.Frontiers in immunology · 2022Article
- Toll-like receptor-9 stimulated plasmacytoid dendritic cell precursors suppress autoimmune neuroinflammation in a murine model of multiple sclerosis.Scientific reports · 2021Article
- Advances of Regulatory B Cells in Autoimmune Diseases.Frontiers in immunology · 2021Review
- Immunosuppressive Mechanisms of Regulatory B Cells.Frontiers in immunology · 2021Review
- Editorial: The Role of Hematopoietic Progenitors in Immune Regulation and Memory.Frontiers in immunology · 2021Article
- The Regulatory Role of IL-10 in Neurodegenerative Diseases.Biomolecules · 2020Review
- Mobilized Multipotent Hematopoietic Progenitors Stabilize and Expand Regulatory T Cells to Protect Against Autoimmune Encephalomyelitis.Frontiers in immunology · 2020Article
- Phenotypes, Functions, and Clinical Relevance of Regulatory B Cells in Cancer.Frontiers in immunology · 2020Review
- Regulatory B Cells and Its Role in Central Nervous System Inflammatory Demyelinating Diseases.Frontiers in immunology · 2020Review
- Estrogen-induced compensatory mechanisms protect IL-10-deficient mice from developing EAE.Journal of neuroinflammation · 2019Article
- Phenotypic identification of CD19Archives of medical science : AMS · 2019Article
- Innate, innate-like and adaptive lymphocytes in the pathogenesis of MS and EAE.Cellular & molecular immunology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The influence of signals perceived by immature B cells during their development in bone marrow on their subsequent functions as mature cells are poorly defined. Here, we show that bone marrow cells transiently stimulated in vivo or in vitro through the Toll-like receptor 9 generate proB cells (CpG-proBs) that interrupt experimental autoimmune encephalomyelitis (EAE) when transferred at the onset of clinical symptoms. Protection requires differentiation of CpG-proBs into mature B cells that home to reactive lymph nodes, where they trap T cells by releasing the CCR7 ligand, CCL19, and to inflamed central nervous system, where they locally limit immunopathogenesis through interleukin-10 production, thereby cooperatively inhibiting ongoing EAE. These data demonstrate that a transient inflammation at the environment, where proB cells develop, is sufficient to confer regulatory functions onto their mature B-cell progeny. In addition, these properties of CpG-proBs open interesting perspectives for cell therapy of autoimmune diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.